Here are the Long-term benefit of SGLT2 inhibitors to prevent heart failure hospitalization in patients with diabetes, with potential time-varying benefit journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Are long term benefits taxable, what is one long term benefit of physical activity, long term benefit of sglt2 inhibitors to lower, long term benefit of sglt2 mechanism, va long term benefits, long term benefit of sglt2 inhibitors list, long term benefit of sglt2 inhibitor, long term care insurance pros and cons, long term care.
Long-term benefit of SGLT2 inhibitors to prevent heart failure hospitalization in patients with diabetes, with potential time-varying benefit
SGLT2 inhibitors show promise in reducing hospitalization for heart failure in diabetics, but their long-term effects and time-dependency remain unclear. We conducted a retrospective nested case–control study within a large type 2 diabetic cohort (n = 11,209) using electronic health records. Cases (heart failure hospitalization, n = 352) were matched to controls (n = 1372) based on age, sex, cohort entry date, and diabetes duration. Matched-set conditional logistic regression was used to estimate hazard ratios (HRs) for antidiabetic drug class and heart failure hospitalization risk. SGLT2 inhibitors were associated with a significant reduction in heart failure hospitalization risk (adjusted HR 0.56, 95% CI 0.38–0.82, p = 0.028). This protective effect appeared more pronounced with a longer duration of treatment, suggesting a potential cumulative benefit. Time-varying analysis within propensity score-matched cohorts revealed a progressive decrease in hospitalization risk w ith continued SGLT2 inhibitor use, indicating a strengthening effect over time (greedy nearest neighbor: HR 0.52, CI 0.31–0.87, p = 0.015; optimal matching: HR 0.54, CI 0.34–0.85, p = 0.008). While promising, further investigation with larger datasets is warranted to definitively confirm these findings. © 2024 The Author(s). Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Authors : Takahashi Y.; Minagawa K.; Nagashima T.; Hayakawa T.; Akimoto H.; Asai S.
Source : John Wiley and Sons Inc
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.1111/cts.70088 |
| ISSN | 17528054 |
| Volume | 17 |
You can download the article here
If You have any problem, contact us here